PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 16, 2026Scripta MedicaOpen Access

A narrative review on preclinical/clinical trials on aducanumab

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAkriti GoelGGG GarimaPJParas Jain

Discussion

Loading...

Member takes

Overview

Narrative review examines preclinical and clinical trials of aducanumab in Alzheimer’s disease, suggesting promise for future treatments.

Key Points

  • This review aims to evaluate the preclinical and clinical evidence supporting aducanumab as a treatment for Alzheimer's disease.
  • Narrative review of existing literature on aducanumab and its impact on Alzheimer's disease.
  • Analysis of preclinical animal studies and human clinical trials regarding amyloid-β targeting.
  • Examination of the development history and regulatory approval process of aducanumab.
  • Aducanumab reduces amyloid-β plaque formation in both animal models and human trials.
  • Approval of aducanumab in 2021 marks a significant milestone in Alzheimer's treatment after a 20-year gap.
  • While aducanumab shows promise, it does not represent a complete cure for Alzheimer's disease but a potential pathway for future research.

Cite This Study

Goel et al. (2026) studied this question.

synapsesocial.com/papers/6a080a11a487c87a6a40bebahttps://doi.org/10.5937/scriptamed57-59386
View Full Paper
Ask AI
Bookmark
Share